TrialStem cell research & therapy2025

Cardio-renal effect of dapagliflozin and dapagliflozin- saxagliptin combination on CD34 + ve hematopoietic stem cells (HSCs) and podocyte specific markers in type 2 diabetes (T2DM) subjects: a randomized trial.

Seshagiri Rao Nandula et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.